TB-500 protocol considerations Reported dosing in the research literature: Starting dose: 500 mcg daily, subcutaneous injection Titration: Increase by 100 to 150 mcg every two weeks as tolerated Target dose: 750 to 1000 mcg daily by weeks five through twelve Weekly total: Approximately 5 mg per week at full dose Cycle length: Eight to twelve weeks, with optional extension to sixteen weeks TB-500 is typically administered once daily via subcutaneous injection, with consistent timing and systematic site rotation
Studies using radiolabeled BPC-157 show that even when injected in a distant location, the peptide migrates to injured tissues throughout the body
Kerksick, C., & Willoughby, D
Manufactured by Fit Aminos to research-grade standards and intended strictly for laboratory and scientific research purposes
Gently swirl until the powder dissolves into a clear solution, usually 1 to 3 minutes
As of September 2023 it is on the FDA Category 2 list of bulk drug substances that may not be compounded, and a PCAC review is scheduled for July 2026 under the name Emideltide